Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 47 Carcinoma, Hepatocellular 9 Triple Negative Breast Neoplasms 7 Stomach Neoplasms 6 Inflammatory Breast Neoplasms 6 Lymphoma, Large B-Cell, Diffuse 4 Urinary Bladder Neoplasms 3 Non-Muscle Invasive Bladder Neoplasms 3 Esophageal Neoplasms 3 Recurrence 2 Lymphoma 2 Breast Neoplasms, Male 2 Breast Diseases 2 Upper Tract Urothelial Carcinoma 1 Thymoma 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Complications 1 Pancreatic Neoplasms 1 Oesophagogastric Cancer 1 Neoplastic Cells, Circulating 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell 1 Lung Neoplasms 1 Liver Neoplasms 1 Leiomyosarcoma 1

Interventions

Neoadjuvant Therapy 1 Lapatinib 1 Epirubicin 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Oesophagogastric Cancer × Epirubicin × Clear all

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡